Cullinan Oncology Inc

Research Cullinan Oncology Inc (CGEM) on Bullrun: market cap USD 1.13B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerCGEM
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 1.13B
• Financial periodFY2025
• Net income-USD 219.88M
• Free cash flow-USD 175.80M

Valuation Snapshot

latest market cap is USD 1.13B.

About Cullinan Oncology Inc

Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases;

Frequently asked questions

What is Cullinan Oncology Inc's market cap?

Cullinan Oncology Inc's market capitalization is USD 1.13B.

What does Cullinan Oncology Inc do?

Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials;